{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T12:46:17Z","timestamp":1775306777621,"version":"3.50.1"},"reference-count":42,"publisher":"Japan Endocrine Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2013]]},"DOI":"10.1507\/endocrj.ej12-0455","type":"journal-article","created":{"date-parts":[[2013,3,26]],"date-time":"2013-03-26T22:46:21Z","timestamp":1364337981000},"page":"861-870","source":"Crossref","is-referenced-by-count":2,"title":["Association of CYP11B2 polymorphisms with susceptibility to primary aldosteronism: a meta-analysis"],"prefix":"10.1507","volume":"60","author":[{"given":"Minyue","family":"Jia","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxiao","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanlan","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenying","family":"Miao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Funder JW (2012) The Genetic Basis of Primary Aldosteronism. <i>Curr Hypertens Rep<\/i> 14: 120-124.","DOI":"10.1007\/s11906-012-0255-x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P (2002) Hyperaldosteronism among black and white subjects with resistant hypertension. <i>Hypertension<\/i> 40: 892-896.","DOI":"10.1161\/01.HYP.0000040261.30455.B6"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, et al. (2008) Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. <i>Lancet<\/i> 371: 1921-1926.","DOI":"10.1016\/S0140-6736(08)60834-X"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, et al. (2008) Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab<\/i> 93: 3266-3281.","DOI":"10.1210\/jc.2008-0104"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Quinkler M, Born-Frontsberg E, Fourkiotis VG (2010) Comorbidities in primary aldosteronism. <i>Horm Metab Res<\/i> 42: 429-434.","DOI":"10.1055\/s-0029-1243257"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Catena C, Colussi G, Marzano L, Sechi LA (2012) Aldosterone and the heart: from basic research to clinical evidence. <i>Horm Metab Res<\/i> 44: 181-187.","DOI":"10.1055\/s-0031-1291318"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Fourkiotis VG, Hanslik G, Hanusch F, Lepenies J, Quinkler M (2012) Aldosterone and the kidney. <i>Horm Metab Res<\/i> 44: 194-201.","DOI":"10.1055\/s-0031-1295461"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, et al. (2006) Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. <i>J Clin Endocrinol Metab<\/i> 91: 454-459.","DOI":"10.1210\/jc.2005-1733"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kunzel HE (2012) Psychopathological symptoms in patients with primary hyperaldosteronism--possible pathways. <i>Horm Metab Res<\/i> 44: 202-207.","DOI":"10.1055\/s-0032-1301921"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Mulatero P, Morello F, Veglio F (2004) Genetics of primary aldosteronism. <i>J Hypertens<\/i> 22: 663-670.","DOI":"10.1097\/00004872-200404000-00001"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. <i>Ann Intern Med<\/i> 127: 820-826.","DOI":"10.7326\/0003-4819-127-9-199711010-00008"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Ioannidis JPA, Patsopoulos NA, Evangelou E (2007) Uncertainty in heterogeneity estimates in meta-analyses. <i>BMJ<\/i> 335: 914-916.","DOI":"10.1136\/bmj.39343.408449.80"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Macaskill P, Walter SD, Irwig L (2001) A comparison of methods to detect publication bias in meta-analysis. <i>Stat Med<\/i> 20: 641-654.","DOI":"10.1002\/sim.698"},{"key":"14","unstructured":"14. Giacchetti G, Lucarelli G, Ronconi V, Arnaldi G, Mantero F (1999) Aldosterone synthase gene polymorphism in idiopathic hyperaldosteronism and essential hypertension. <i>Hypertension<\/i> 34: 697-697."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Regolisti G, Giacchetti G, Lucarelli G, Ronconi V, Arnaldi G, et al. (2000) Aldosterone synthase gene polymorphism in idiopathic hyperaldosteronism. <i>J Hypertens<\/i> 18 Supplement: S144.","DOI":"10.1097\/00004872-200006001-00492"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Rossi E, Regolisti G, Perazzoli F, Negro A, Davoli S, et al. (2001) -344C\/T polymorphism of CYP11B2 gene in Italian patients with idiopathic low renin hypertension. <i>Am J Hypertens<\/i> 14: 934-941.","DOI":"10.1016\/S0895-7061(01)02138-0"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Jeske Y, So A, Gordon R, Duffy D, Stowasser M (2005) No association between primary aldosteronism and two CYP11B2 polymorphisms in a well-characterized Australian sample. <i>Am J Hypertens<\/i> 18: 6A-6A.","DOI":"10.1016\/j.amjhyper.2005.03.012"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Zhang GX, Wang BJ, Ouyang JZ, Deng XY, Ma X, et al. (2010) Polymorphisms in CYP11B2 and CYP11B1 genes associated with primary hyperaldosteronism. <i>Hypertens Res<\/i> 33: 478-484.","DOI":"10.1038\/hr.2010.21"},{"key":"19","unstructured":"19. Deng XY, Zhang X (2010) Association between the incidence of aldosterone-producing adenoma and the C-344T single nucleotide polymorphism of CYP11B2 gene promoter. <i>J Med Urol<\/i> 15: 336-337 (In Chinese)."},{"key":"20","unstructured":"20. Guo RM, Gong YC, Guo YZ, Chu SL, Zhu DL (2011) Genotype research main subtypes of on Primary aldosteronism. <i>Med Theo &amp; Prac<\/i> 6: 135-139 (In Chinese)."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Tanahashi H, Mune T, Takahashi Y, Isaji M, Suwa T, et al. (2005) Association of Lys173Arg polymorphism with CYP11B2 expression in normal adrenal glands and aldosterone-producing adenomas. <i>J Clin Endocrinol Metab<\/i> 90: 6226-6231.","DOI":"10.1210\/jc.2005-0299"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Stowasser M, Gordon RD (2003) Primary aldosteronism: from genesis to genetics. <i>Trends Endocrinol Metab<\/i> 14: 310-317.","DOI":"10.1016\/S1043-2760(03)00112-7"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Mulatero P, Schiavone D, Fallo F, Rabbia F, Pilon C, et al. (2000) CYP11B2 gene polymorphisms in idiopathic hyperaldosteronism. <i>Hypertension<\/i> 35: 694-698.","DOI":"10.1161\/01.HYP.35.3.694"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Bassett MH, Zhang Y, Clyne C, White PC, Rainey WE (2002) Differential regulation of aldosterone synthase and 11beta-hydroxylase transcription by steroidogenic factor-1. <i>J Mol Endocrinol<\/i> 28: 125-135.","DOI":"10.1677\/jme.0.0280125"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Ye P, Nakamura Y, Lalli E, Rainey WE (2009) Differential effects of high and low steroidogenic factor-1 expression on CYP11B2 expression and aldosterone production in adrenocortical cells. <i>Endocrinology<\/i> 150: 1303-1309.","DOI":"10.1210\/en.2008-0667"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Bassett MH, Suzuki T, Sasano H, White PC, Rainey WE (2004) The orphan nuclear receptors NURR1 and NGFIB regulate adrenal aldosterone production. <i>Mol Endocrinol<\/i> 18: 279-290.","DOI":"10.1210\/me.2003-0005"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Takeda Y, Furukawa K, Inaba S, Miyamori I, Mabuchi H (1999) Genetic analysis of aldosterone synthase in patients with idiopathic hyperaldosteronism. <i>J Clin Endocrinol Metab<\/i> 84: 1633-1637.","DOI":"10.1210\/jc.84.5.1633"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Miyamori I, Inaba S, Hatakeyama H, Taniguchi N, Takeda Y (2000) Idiopathic hyperaldosteronism: analysis of aldosterone synthase gene. <i>Biomed Pharmacother<\/i> 54 Suppl 1: 77s-79s.","DOI":"10.1016\/S0753-3322(00)80017-7"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Connell JM, Fraser R, MacKenzie SM, Friel EC, Ingram MC, et al. (2004) The impact of polymorphisms in the gene encoding aldosterone synthase (CYP11B2) on steroid synthesis and blood pressure regulation. <i>Mol Cell Endocrinol<\/i> 217: 243-247.","DOI":"10.1016\/j.mce.2003.10.025"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Stowasser M, Gordon RD (2003) Primary aldosteronism: from genesis to genetics. <i>Trends in Endocrinology and Metabolism<\/i> 14: 310-317.","DOI":"10.1016\/S1043-2760(03)00112-7"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Zennaro MC, Jeunemaitre X, Boulkroun S (2012) Integrating genetics and genomics in primary aldosteronism. <i>Hypertension<\/i> 60: 580-588.","DOI":"10.1161\/HYPERTENSIONAHA.111.188250"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Choi M, Scholl UI, Yue P, Bjorklund P, Zhao B, et al. (2011) K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. <i>Science<\/i> 331: 768-772.","DOI":"10.1126\/science.1198785"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Azizan EA, Murthy M, Stowasser M, Gordon R, Kowalski B, et al. (2012) Somatic mutations affecting the selectivity filter of KCNJ5 are frequent in 2 large unselected collections of adrenal aldosteronomas. <i>Hypertension<\/i> 59: 587-591.","DOI":"10.1161\/HYPERTENSIONAHA.111.186239"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Xekouki P, Hatch MM, Lin L, Rodrigo de A, Azevedo M, et al. (2012) KCNJ5 mutations in the National Institutes of Health cohort of patients with primary hyperaldosteronism: an infrequent genetic cause of Conn&rsquo;s syndrome. <i>Endocr Relat Cancer<\/i> 19: 255-260.","DOI":"10.1530\/ERC-12-0022"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Taguchi R, Yamada M, Nakajima Y, Satoh T, Hashimoto K, et al. (2012) Expression and mutations of KCNJ5 mRNA in Japanese patients with aldosterone-producing adenomas. <i>J Clin Endocrinol Metab<\/i> 97: 1311-1319.","DOI":"10.1210\/jc.2011-2885"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Condon JC, Pezzi V, Drummond BM, Yin S, Rainey WE (2002) Calmodulin-dependent kinase I regulates adrenal cell expression of aldosterone synthase. <i>Endocrinology<\/i> 143: 3651-3657.","DOI":"10.1210\/en.2001-211359"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Sackmann S, Lichtenauer U, Shapiro I, Reincke M, Beuschlein F (2011) Aldosterone producing adrenal adenomas are characterized by activation of calcium\/calmodulin-dependent protein kinase (CaMK) dependent pathways. <i>Horm Metab Res<\/i> 43: 106-111.","DOI":"10.1055\/s-0030-1269899"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Williams TA, Monticone S, Crudo V, Warth R, Veglio F, et al. (2012) Visinin-like 1 is upregulated in aldosterone-producing adenomas with KCNJ5 mutations and protects from calcium-induced apoptosis. <i>Hypertension<\/i> 59: 833-839.","DOI":"10.1161\/HYPERTENSIONAHA.111.188532"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Williams TA, Monticone S, Morello F, Liew CC, Mengozzi G, et al. (2010) Teratocarcinoma-derived growth factor-1 is upregulated in aldosterone-producing adenomas and increases aldosterone secretion and inhibits apoptosis in vitro. <i>Hypertension<\/i> 55: 1468-1475.","DOI":"10.1161\/HYPERTENSIONAHA.110.150318"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Qi Y, Niu W, Zhu T, Zhou W, Qiu C (2008) Synergistic effect of the genetic polymorphisms of the renin-angiotensin-aldosterone system on high-altitude pulmonary edema: a study from Qinghai-Tibet altitude. <i>Eur J Epidemiol<\/i> 23: 143-152.","DOI":"10.1007\/s10654-007-9208-0"},{"key":"41","unstructured":"41. Fardella CE, Rodriguez H, Montero J, Zhang G, Vignolo P, et al. (1996) Genetic variation in P450c11AS in Chilean patients with low renin hypertension. <i>J Clin Endocrinol Metab<\/i> 81: 4347-4351."},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Young WF Jr. (2010) Endocrine hypertension: then and now. <i>Endocr Pract<\/i> 16: 888-902.","DOI":"10.4158\/EP10205.RA"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/60\/7\/60_EJ12-0455\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T06:38:37Z","timestamp":1618295917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/60\/7\/60_EJ12-0455\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej12-0455","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}